Recent Cancer Papers

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.Van Allen, EM, Wagle N., Stojanov P., Perrin DL, Cibulskis K., Marlow S., Jane-Valbuena J., Friedrich DC, Kryukov G., Carter SL, McKenna A., Sivachenko A., Rosenberg M., Kiezun A., Voet D., Lawrence M., Lichtenstein LT, Gentry JG, Huang FW, Fostel J., et al. Nature medicine, 2014/06/01, Volume 20, Issue 6, p.682-8, (2014) Read More / View Supplemental Materials
Abstract
Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing.Helman, E., Lawrence ML, Stewart C., Sougnez C., Getz G., and Meyerson M. Genome research, 2014/05/13, (2014) Read More / View Supplemental Materials
Abstract
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.Lohr, JG, Adalsteinsson VA, Cibulskis K., Choudhury AD, Rosenberg M., Cruz-Gordillo P., Francis JM, Zhang CZ, Shalek AK, Satija R., Trombetta JJ, Lu D., Tallapragada N., Tahirova N., Kim S., Blumenstiel B., Sougnez C., Lowe A., Wong B., Auclair D., et al. Nature biotechnology, 2014/05/01, Volume 32, Issue 5, p.479-84, (2014) Read More / View Supplemental Materials
Abstract
Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.Wang, L., Shalek AK, Lawrence M., Ding R., Gaublomme JT, Pochet N., Stojanov P., Sougnez C., Shukla SA, Stevenson KE, Zhang W., Wong J., Sievers QL, Macdonald BT, Vartanov AR, Goldstein NR, Neuberg D., He X., Lander E., Hacohen N., et al. Blood, 2014/04/28, (2014) Read More / View Supplemental Materials
Abstract
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.Konieczkowski, DJ, Johannessen CM, Abudayyeh O., Kim JW, Cooper ZA, Piris A., Frederick DT, Barzily-Rokni M., Straussman R., Haq R., Fisher DE, Mesirov J. P., Hahn WC, Flaherty KT, Wargo JA, Tamayo P., and Garraway LA Cancer discovery, 2014/04/25, (2014) Read More / View Supplemental Materials
Abstract
Targeted genomic rearrangements using CRISPR/Cas technology.Choi, PS, and Meyerson M. Nature communications, 2014/04/24, Volume 5, p.3728, (2014) Read More / View Supplemental Materials
Abstract
A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein.Pop, MS, Stransky N., Garvie CW, Theurillat JP, Lewis TA, Zhong C., Culyba EK, Lin F., Daniels DS, Pagliarini R., Ronco L., Koehler AN, and Garraway LA Molecular cancer therapeutics, 2014/04/15, (2014) Read More / View Supplemental Materials
Abstract
SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas.Watanabe, H., Ma Q., Peng S., Adelmant G., Swain D., Song W., Fox C., Francis JM, Pedamallu CS, Deluca DS, Brooks AN, Wang S., Que J., Rustgi AK, Wong KK, Ligon KL, Liu XS, Marto JA, Meyerson M., and Bass AJ The Journal of clinical investigation, 2014/04/01, Volume 124, Issue 4, p.1636-45, (2014) Read More / View Supplemental Materials
Abstract
Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib.Wagle, N., Grabiner BC, Van Allen EM, Hodis E., Jacobus S., Supko JG, Stewart M., Choueiri TK, Gandhi L., Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S., Loda M., Shapiro GI, Sabatini DM, Lander E. S., Gabriel SB, Kantoff PW, et al. Cancer discovery, 2014/03/27, (2014) Read More / View Supplemental Materials
Abstract
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing.McFadden, DG, Papagiannakopoulos T., Taylor-Weiner A., Stewart C., Carter SL, Cibulskis K., Bhutkar A., McKenna A., Dooley A., Vernon A., Sougnez C., Malstrom S., Heimann M., Park J., Chen F., Farago AF, Dayton T., Shefler E., Gabriel S., Getz G., et al. Cell, 2014/03/13, Volume 156, Issue 6, p.1298-311, (2014) Read More / View Supplemental Materials
Abstract
ARID1B is a specific vulnerability in ARID1A-mutant cancers.Helming, KC, Wang X., Wilson BG, Vazquez F., Haswell JR, Manchester HE, Kim Y., Kryukov GV, Ghandi M., Aguirre AJ, Jagani Z., Wang Z., Garraway LA, Hahn WC, and Roberts CW Nature medicine, 2014/03/01, Volume 20, Issue 3, p.251-4, (2014) Read More / View Supplemental Materials
Abstract
Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation.Wilson, BG, Helming KC, Wang X., Kim Y., Vazquez F., Jagani Z., Hahn WC, and Roberts CW Molecular and cellular biology, 2014/03/01, Volume 34, Issue 6, p.1136-44, (2014) Read More / View Supplemental Materials
Abstract
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.Brastianos, PK, Taylor-Weiner A., Manley PE, Jones RT, Dias-Santagata D., Thorner AR, Lawrence MS, Rodriguez FJ, Bernardo LA, Schubert L., Sunkavalli A., Shillingford N., Calicchio ML, Lidov HG, Taha H., Martinez-Lage M., Santi M., Storm PB, Lee JY, Palmer JN, et al. Nature genetics, 2014/02/01, Volume 46, Issue 2, p.161-5, (2014) Read More / View Supplemental Materials
Abstract
Oncogenic RIT1 mutations in lung adenocarcinoma.Berger, AH, Imielinski M., Duke F., Wala J., Kaplan N., Shi GX, Andres DA, and Meyerson M. Oncogene, 2014/01/27, (2014) Read More / View Supplemental Materials
Abstract
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.Dunn, GP, Cheung HW, Agarwalla PK, Thomas S., Zektser Y., Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L., Getz G., Liu JF, Hirsch M., Vazquez F., Root DE, Beroukhim R., Drapkin R., and Hahn WC Proceedings of the National Academy of Sciences of the United States of America, 2014/01/21, Volume 111, Issue 3, p.1102-7, (2014) Read More / View Supplemental Materials
Abstract
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.Zhu, Z., Aref AR, Cohoon TJ, Barbie TU, Imamura Y., Yang S., Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P., Godfrey JT, Qian ZR, Page AN, Maciag K., Chan EM, Silkworth W., Labowsky MT, Rozhansky L., et al. Cancer discovery, 2014/01/20, (2014) Read More / View Supplemental Materials
Abstract
ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State.Chudnovsky, Y., Kim D., Zheng S., Whyte WA, Bansal M., Bray MA, Gopal S., Theisen MA, Bilodeau S., Thiru P., Muffat J., Yilmaz OH, Mitalipova M., Woolard K., Lee J., Nishimura R., Sakata N., Fine HA, Carpenter AE, Silver SJ, et al. Cell reports, 2014/01/15, (2014) Read More / View Supplemental Materials
Abstract
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.Lohr, JG, Stojanov P., Carter SL, Cruz-Gordillo P., Lawrence MS, Auclair D., Sougnez C., Knoechel B., Gould J., Saksena G., Cibulskis K., McKenna A., Chapman MA, Straussman R., Levy J., Perkins LM, Keats JJ, Schumacher SE, Rosenberg M., Multiple Myeloma Research Consortium, et al. Cancer cell, 2014/01/13, Volume 25, Issue 1, p.91-101, (2014) Read More / View Supplemental Materials
Abstract
Discovery and saturation analysis of cancer genes across 21 tumour types.Lawrence, MS, Stojanov P., Mermel CH, Robinson JT, Garraway LA, Golub T. R., Meyerson M., Gabriel SB, Lander E. S., and Getz G. Nature, 2014/01/05, (2014) Read More / View Supplemental Materials
Abstract
A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events.Brooks, AN, Choi PS, de Waal L., Sharifnia T., Imielinski M., Saksena G., Pedamallu CS, Sivachenko A., Rosenberg M., Chmielecki J., Lawrence MS, Deluca DS, Getz G., and Meyerson M. PloS one, 2014/01/01, Volume 9, Issue 1, p.e87361, (2014) Read More / View Supplemental Materials
Abstract